Moringa oleifera offers a multi-mechanistic approach for management of obesity in rats

International Journal of Pharmaceutical Sciences Review and Research

Volumn 29, Issue 2, 2014, Pages 98-106

  Ahmed, Hanaa H ^a   Metwally, Fateheya M ^a   Rashad, Hend ^a   Zaazaa, Asmaa M ^b   Ezzat, Shahira M ^c   Salama, Maha M ^c  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b Ain Shams University   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Dyslipidemia; Malondialdehyde; Moringa oleifera; Nitric oxide; Obesity; Simvastatin

Indexed keywords

ADIPONECTIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LEPTIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MORINGA OLEIFERA EXTRACT; NITRIC OXIDE; RESISTIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL CIRCUMFERENCE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMICAL ANALYSIS; BODY MASS; CARBOHYDRATE INTAKE; CHEST CIRCUMFERENCE; CHOLESTEROL DIET; CONTROLLED STUDY; DIETARY FIBER; DRUG ACTIVITY; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOD INTAKE; HYPERLEPTINEMIA; HYPOADIPONECTINEMIA; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN INTAKE; RAT;

EID: 84976294036     PISSN: 0976044X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. WHO, Obesity and overweight, WHO: World Health Organization, 2013.
2. Graves BW, The obesity epidemic: scope of the problem and management strategies, J Midwifery Womens Health, 55(6), 2010, 568-78.
3. Heal DJ, Gosden J, Smith SL, A review of late-stage CNS drug candidates for the treatment of obesity, International Journal of Obesity, 37, 2013, 107-117
4. Mackenbach JP, Stirbu I, Roskam AJR, Schaap MM, Menvielle G, Leinsalu M, Socioeconomic inequalities in health in 22 European countries, N Engl J Med, 358, 2008, 2468-81.
5. Chao C, Shih C, Wang C, Wu J, Lu F, Chang C, Yang Y, Low socioeconomic status may increase the risk of central obesity in incoming university students in Taiwan, Obesity Research & Clinical Practice, 8, 2014, 212-219.
6. Mun EC, Blackburn GL, Matthews JB, Current status of medical and surgical therapy for obesity, Gastroenterology, 120 (3), 2001, 669-681.
7. Wooding AE, Rehman I, Obesity and prostate cancer: Is there a link, e-SPEN Journal, 9, 2014, e123ee130.
8. McGovern L, Johnson JN, Paulo R, Hettinger A, Singhal V, Kamath C, Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials, J Clin Endocrinol Metab., 93, 2008, 4600-4605.
9. Chaput JP, St-Pierre S, Tremblay A, Currently available drugs for the treatment of obesity: sibutramine and orlistat, Mini Rev Med Chem., 7, 2007, 3-10.
10. Poston WS, Foreyt JP, Sibutramine and the management of obesity, Expert Opin Pharmacother., 5, 2004, 633-642.
11. Tziomalos K, Krassas GE, Tzotzas T, The use of sibutramine in the management of obesity and related disorders: an update, Vasc Health RisManag, 5, 2009, 441-452.
12. Slovacek L, Pavlik V, Slovackova B, The effect of sibutramine therapy on occurrence of depression symptoms among obese patients, Nutr Metab Cardiovasc Dis., 18, 2008, e43-e44.
13. Karamadoukis L, Shivashankar GH, Ludeman L Williams AJ, An unusual complication of treatment with orlistat, Clin Nephrol., 71, 2009, 430-432.
14. Halford JC, Obesity drugs in clinical development, Curr Opin Invest Drugs, 7, 2006, 312-318.
15. Melnikova I, Wages D, Anti-obesity therapies, Nat Rev Drug Discov., 5, 2006, 369-370.
16. Nakayama T, Suzuki S, Kudo H, Sassa S, Nomura M, Sakamoto S, Effects of three Chinese herbal medicines on plasma and liver lipids in mice fed a highfat diet, J Ethnopharmacol., 109, 2007, 236-240.
17. Mayer MA, Hocht C, Puyo A, Taira CA, Recent advances in obesity pharmacotherapy, Curr Clin Pharmacol, 4, 2009, 53-61.
18. Han LK, Kimura Y, Okuda H, Anti-obesity effects of natural products, Stud Nat Prod Chem., 30, 2005, 79-110.
19. Rayalam S, Della-Fera MA, Baile CA, Phytochemicals and regulation of the adipocyte life cycle, J Nutr Biochem., 19, 2008, 717-726.
20. Ramachandran C, Peter KV, Gopalakrishan PK, Drumstick (Moringa oleifera). A multi-purpose Indian vegetable, Economic Botany, 34(3), 1980, 276-282.
21. Sofowora A, Medicinal plants and traditional medicine in Africa. John Wiley and Sons Ltd, New York, 1982, 214-218.
22. Ghasi S, Nwobodo E, Ofili JO, Hypocholesterolemic effects of crude extract of leaf of Moringa oleifera Lam in high fat diet fed wistar rats, Journal of Ethnopharmacology, 69(1), 2000, 21-25.
23. Dangi SY, Jolly CI, Narayanan S, Antihypertensive activity of the total alkaloids from the leaves of Moringa oleifera, J pharmaceutical biology, 40(2), 2002, 144-148.
24. Soliman MM, Attia HF, El-Shazly SA, Saleh OM, Biomedical effects of cinnamon extract on obesity and diabetes relevance in Wistar rats, Am J Biochem Mol Biol., 2, 2012, 133-145.
25. Novelli EL, Diniz YS, Galhardi CM, Ebaid GM, Rodrigues HG, Anthropometrical parameters and markers of obesity in rats, Lab Anim., 41, 2007, 111-119.
26. Jain PG, Patil SD, Haswani NG, Girase MV, Surana SJ, Hypolipidemic activity of Moringa oleifera Lam., Moringaceae, on high fat diet induced hyperlipidemia in albino rats, Brazilian Journal of Pharmacognosy, 20(6), 2010, 969-973.
27. Mbikay M, Therapeutic potential of Moringa olifera leaves in chronic hyperglycemia and dyslipidemia: a review, Frontiers in pharmacology, 3(24), 2012, 1-12.
28. Meiattini F, The 4-hydroxybenzoate/4-aminophenazone chromogenic system, Clin Chem., 24(12), 1978, 2161-2165.
29. Buccolo G, Quantitative determination of serum triglycerides by use of enzymes, Clin Chem., 19(5), 1973, 476-482.
30. Naito HK, HDL Cholesterol, Kaplan A, Clin Chem The C.V. Mosby Co. St Louis, Toronto, Princeton, 1984, 1207-1213 and 437.
31. Wieland H, Seidel D, J-Lipid Res., 24, 1983, 904.
32. Satoh K, Serum lipid peroxide in Cerebrovascular disorders determined by a new colorimetric method, Clinica Chimica Acta, 90, 1978, 37-43.
33. Montgoery HAC, Dymock JF, Analyst, 86, 1961, 414.
34. Yun JW, Possible anti-obesity therapeutics from nature-A review, Phytochemistry, 71, 2010, 1625-1641.
35. Rodrigues A, Pereira PC, Vicente AF, Brito JA, Bernardo MA, Mesquita MF, Food intake, body mass index and body fat mass in elderly, Asian J Clin Nutr., 4, 2012, 107-115.
36. Dongmeza E, Siddhuraju P, Francis G, Becker K, Effects of dehydrated methanol extracts of moringa (Moringa oleifera Lam.) Leaves and three of its fractions on growth performance and feed nutrient assimilation in Nile tilapia (Oreochromis niloticus (L.), Aquaculture, 261, 2006, 407-422.
37. Koh KK, Quon MJ, Han SH, Lee Y, Kim, SJ, Park JP Shin EK, Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients, Atherosclerosis, 204, 2009, 483-490.
38. Ballantyne, CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J, Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S, Circulation, 104, 2001, 3046-3051.
39. Son EL, Pal UK, Mandal PK, Hong GE, Kim SK, Lee CH, Hypolipidaemic effect of processed sulfur, Allium tuberosum rottl. and fermented Allium tuberosum rottl in rat, Asian J Anim Vet Adv., 7, 2012, 812-821.
40. Fruchart JC, Brewer HB, Leitersdorf E, Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group, Am J Cardiol., 81, 1998, 912-917.
41. Raveh O, Pinchuk I, Fainaru M, Lichtenberg D, Kinetics of lipid peroxidation in mixture of HDL and LDL, mutual effects, Free Radic Biol Med., 31, 2001, 1486-1497.
42. Hassarajani S, Souza TD, Mengi SA, Efficacy study of the bioactive fraction (F-3) of Acorus calamus in hyperlipidemia, Indian J Pharmacol, 39, 2007, 196-200.
43. Anwar F, Latif S, Ashraf M, Gilani AH, Review Moringa oleifera: A food plant with multiple medicinal uses, Phytotherapy Res., 21(1), 2007, 17-25.
44. Saluja MP, Kapil RS, Popli SP, Studies in medicinal plants: part VI. Chemical constituents of Moringa oleifera Lamk. (hybrid variety) and isolation of 4-hydroxymellein, Indian Journal of Chemistry, 16(11), 1978, 1044-1045.
45. Kane JP, Malloy MJ, Treatment of hypercholesterolemia, Medical Clinics of North America, 66, 1982, 537-550.
46. O’Byme DJ, Devaraj S, Grundy SM, Jialal I, Comparison of antioxidant effects of Concord grape juice flavonoids and α-tocopherol on markers of oxidative stress in healthy adults, Am J Clin Nutr., 76, 2002, 1367-1374.
47. Matikainen N, Kahri J, Taskinen MR, “Reviewing statin therapy in diabetes-towards the best practice,” Primary Care Diabetes, 4 (1), 2010, 9-15.
48. Yao XM, Ye SD, Zai Z, “Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression,” Journal of Endocrinological Investigation, 33(5), 2010, 292–296.
49. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B, Simvastatin prevents angiotensin II induced cardiac alterations and oxidative stress, Hypertension, 40, 2002, 142-7.
50. Prasanna GS, Purnima A, Protective effect of leaf extract of Trichilia connaroides on hypercholesterolemia induced oxidative stress, Int J Pharmacol., 7, 2011, 106-112.
51. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC, Panov Mitochondrial disease in mouse results in increased oxidative stress, Proc National Acad Sci, 96, 1999, 4820-4825.
52. Sreelatha S, Padma PR, Antioxidant Activity and Total Phenolic Content of Moringa oleifera Leaves in Two Stages of Maturity, Plant Foods Hum Nutr, 2009, 64, 303-311.
53. Heeba G, Moselhy ME, Hassan M, Khalifa M, Gryglewski R, Malinski TI, Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1, British Journal of Pharmacology, 156, 2009, 1256-1266.
54. Sabri M, Jinglu A, Philip A, Macdonald RL, Simvastatin recouples dysfunctional endothelial nitric oxide synthase in experimental subarachnoid hemorrhage, PLoS One 6, 2011, ē17062.
55. Elizalde M, Ryden M, van Harmelen V, Eneroth P, Gyllenhammar H, Holm C, Ramel S, Olund A, Arner P, Andersson K, Expression of nitric oxide synthases in subcutaneous adipose tissue of non obese and obese humans, J Lipid Res., 41, 2000, 1244-1251.
56. Park E, Cheenpracha S, Chang LC, Kondratyuk TP, Pezzuto JM, Inhibition of Lipopolysaccharide-Induced Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Expression by 4-[(2′-Oacetyl-α-L-Rhamnosyloxy)Benzyl]Isothiocyanate from Moringa oleifera, Nutrition and Cancer, 63 (6), 2011, 971-982.
57. Wagner AH, Schwabe O, Hecker M, Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ, Br J Pharmacol., 136, 2002, 143-149.
58. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC, Panov Mitochondrial disease in mouse results in increased oxidative stress, Proc National Acad Sci., 96, 1999, 4820-4825.
59. Bingham NC, Anderson KK, Reuter AL, Stallings NR, Parker KL, Selective loss of leptin receptors in the ventromedial hypothalamic nucleus results in increased adiposity and a metabolic syndrome, Endocrinology, 149, 2008, 2138-48.
60. Gulturk S, Cetin A, Erdal S, Association of leptin with insulin resistance, body composition, and lipid parameters in postmenopausal women and men in type 2 diabetes mellitus, Saudi Med J., 29, 2008, 813-20.
61. Assal HS, Fath-Allah M, Elsherbiny A, Serum leptin and adiponectin in obese diabetic and non-diabetic, J Med Sci., 7, 2007, 865-869.
62. Xu F, Chen M, Wang Y, Yi Q, Lin S, Chen A, Luo J, Leptin Induces Hypertrophy via Endothelin-1-Reactive Oxygen Species Pathway in Cultured Neonatal Rat Cardiomyocytes, Circulation, 110, 2004, 1269-1275.
63. Maeda T, Horiuchi N, Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation, J Biochem, 145, 2009, 771-781.
64. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF, (1995): A novel serum protein similar to C1q, produced exclusively inadipocytes, J. Biol. Chem., 270, 1995, 26746-26749.
65. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA, Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia, J Clin Endocrinol Metab, 86, 2001, 1930-1935.
66. Berg AH, Combs TP, Scherer PE, ACRP30/adipo-nectin: an adipokine regulating glucose and lipid metabolism, Trends Endocrinol Metab., 13, 2002, 84-89.
67. Festa A, D'Agostino R J, Howard G, Mykkänen L, Tracy RP, Haffner SM, Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS), Circulation, 102, 2000, 42-47.
68. Wellen KE, Hotamisligil GS, Inflammation, stress, and diabetes, J Clin Invest, 115, 2005, 1111-1119.
69. Mahajan SG, Mali RG, Mehta AA, Protective Effect of Ethanolic Extract of Seeds of Moringa oleifera Lam. Against Inflammation Associated with Development of Arthritis in Rats, J Immuno toxicology, 4 (1), 2007, 39-47.
70. Cheenpracha S, Park E, Yoshida WY, Barit C, Wallc M, Pezzuto JM, Chang LC, Potential anti-inflammatory phenolic glycosides from the medicinal plant Moringa oleifera fruits, Bioorganic & Medicinal Chemistry, 18(17), 2010, 6598-6602.
71. Blanco-Colioa LM, Martín-Venturaa JL, Gómez-Guerreroa C, Masramonb X, Teresac E, Farsangd C, Gawe A, Gensinif G, Leiterg LA, Langerg A, Egido J, Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk, European Journal of Pharmacology, 586, 1-3, 2008, 259-265.
72. Kusminski CM, Mcternan PG, Kumar S, Role of resistin in obesity, insulin resistance and Type II diabetes, Clinical Science, 109, 2005, 243-256.
73. Kasera S, Kaserb A, Sandhofera A, Ebenbichlera CF, Tilgb H, Patsch JR, Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro, Biochemical and Biophysical Research Communications, 309(2), 2003, 286-290.
74. Zhao SP, Wu ZH, Wu J, Effect of atorvastatin on tumor necrosis factor alpha serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits, J Cardiovasc Pharmacol., 46, 2005, 185-189.
75. Wu Z, Chen Y, Zhao S, Simvastatin inhibits ox-LDL-induced inflammatory adipokines secretion via amelioration of ER stress in 3T3-L1 adipocyte. Biochemical and Biophysical Research Communications, 432, 2013, 365-369.